On June 30, 2025, Celcuity Inc. announced preliminary clinical data showing a 66% six-month radiographic progression-free survival rate for gedatolisib in a study involving prostate cancer patients. No patients discontinued treatment due to adverse events, and the results will be presented at an upcoming medical conference.